ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Genetically attenuated PfSPZ Vaccine

Its studies are mostly in Malaria, Falciparum, led by Sanaria.

Furthest: phase 2, since Jan 27, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanaria11 open or runningphase 2since Jan 27, 2026Jan 27, 2026Feb 2027phase 2 · NCT07385287

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2026First study: phase 2 study in Malaria, FalciparumFirst studyNCT07385287 · 180 planned · Burkina Faso

Ahead

  1. Feb 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07385287

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Genetically attenuated PfSPZ Vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07385287Malaria, Falciparum · Burkina Faso2RecruitingFeb 2027180

How it is read

Names in the registry

  • “Genetically attenuated PfSPZ Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.